

DAFTAR PUSTAKA

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J Autoimmun* [Internet]. 2020;109(March):102433. Available from: <https://doi.org/10.1016/j.jaut.2020.102433>
2. WHO. Responding to community spread of COVID-19. Interim Guid [Internet]. 2020;(March):1–6. Available from: <https://www.who.int/publications/i/item/responding-to-community-spread-of-covid-19>
3. Yuliana Y. Corona virus diseases (Covid-19): Sebuah tinjauan literatur. *Wellness Heal Mag*. 2020;2(1):187–92.
4. WHO Indonesia Situation Report-42 [who.int/indonesia Situation Report-7](https://www.who.int/indonesia-situation-report-7) [Internet]. [cited 2021 Jun 22]. Available from: <https://en.tempo.co/read/1430857/govt-introduces-micro-ppkm-community-level-social-restriction>
5. Keputusan Presiden RI. Keppres No. 12 Tahun 2020 Tentang Penetapan Bencana Nonalam Penyebaran Corona Virus Disease 2019 Sebagai Bencana Nasional. *Fundam Nurs*. 2020;(01):1–2.
6. Worldmeters.info [Internet]. [cited 2021 Jul 2]. Available from: [http://ww1.worldmeters.info/?terms=Virus Statistical Data Analysis Tools,Population Statistical Data Analysis Tools,Dynamic Data Visualization Tools,World Knowledge Base Software](http://ww1.worldmeters.info/?terms=Virus%20Statistical%20Data%20Analysis%20Tools,Population%20Statistical%20Data%20Analysis%20Tools,Dynamic%20Data%20Visualization%20Tools,World%20Knowledge%20Base%20Software)
7. Beranda | Covid19.go.id [Internet]. [cited 2021 Jul 2]. Available from: <https://covid19.go.id/>
8. Kemenkes RI. Kementerian Kesehatan Republik Indonesia [Internet]. [cited 2021 Nov 14]. Available from: <https://www.kemkes.go.id/article/print/20101400002/13-2-persen-pasien-covid-19-yang-meninggal-memiliki-penyakit-hipertensi.html>
9. Caliskan T, Saylan B. Smoking and comorbidities are associated with COVID-19 severity and mortality in 565 patients treated in Turkey: A retrospective observational study. *Rev Assoc Med Bras*. 2020;66(12):1679–84.
10. WHO. Therapeutics and COVID-19 (20/11/20). *World Heal Organ*. 2020;(November):10.
11. Mortality Analyses - Johns Hopkins Coronavirus Resource Center [Internet]. [cited 2022 Jan 10]. Available from: <https://coronavirus.jhu.edu/data/mortality>

12. WHO. COVID-19 Weekly Epidemiological Update. 2021;(November).
13. Cai H. Sex difference and smoking predisposition in patients with COVID-19. *Lancet Respir Med* [Internet]. 2020;8(4):e20. Available from: [http://dx.doi.org/10.1016/S2213-2600\(20\)30117-X](http://dx.doi.org/10.1016/S2213-2600(20)30117-X)
14. Lei Fang, George Karakiulakis *Michael Roth. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *The. Lancet Respir Med*. 2019;8(4):e21.
15. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. *J Penyakit Dalam Indones*. 2020;7(1):45.
16. Atmojo JT, Arradini D, Darmayanti AT, Widiyanti A, Handayani RT. Dampak merokok terhadap COVID-19. *J Ilm Pemas J Ilm STIKES Kendal* [Internet]. 2021;11(1):169–76. Available from: <http://journal.stikeskendal.ac.id/index.php/PSKM/article/view/1143>
17. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). *J Clin Med*. 2020;9(3):841.
18. Hidayani WR. Faktor Faktor Risiko Yang Berhubungan Dengan COVID 19 : Literature Review. *J Untuk Masy Sehat*. 2020;4(2):120–34.
19. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin Res Cardiol*. 2020;109(5):531–8.
20. Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. *Crit Care*. 2020;24(1):1–9.
21. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. *J Infect Public Health* [Internet]. 2020;13(12):1833–9. Available from: <https://doi.org/10.1016/j.jiph.2020.07.014>
22. Cen Y, Chen X, Shen Y, Zhang X, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019da multi-centre observational study. 2020;(January).
23. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. 2020;(January):19–21.
24. Nindrea RD. Pengantar langkah-langkah praktis studi meta analisis. Yogyakarta Gosyen Publ. 2016;

25. Sinaga DA. Virus Corona: Hal-hal apa yang perlu diketahui. Perki [Internet]. 2020;2. Available from: [http://www.inaheart.org/perki/upload/files/corona virus - dasdo for kagama.pdf](http://www.inaheart.org/perki/upload/files/corona%20virus%20-%20dasdo%20for%20kagama.pdf)
26. Vina Oktiani W. Corona Virus. Available from: [https://wolipop.detik.com/health-and-diet/d-4946027/apa-yang-dimaksud-virus-corona-ini-asal- mula-hingga-gejala-covid-19](https://wolipop.detik.com/health-and-diet/d-4946027/apa-yang-dimaksud-virus-corona-ini-asal-mula-hingga-gejala-covid-19)
27. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 2021 Jun 22]. Available from: <https://covid19.who.int/>
28. Infeksi Emerging Kementerian Kesehatan RI [Internet]. [cited 2021 Jun 22]. Available from: <https://infeksiemerging.kemkes.go.id/>
29. Prasad N, Gopalakrishnan N, Sahay M, Gupta A, Agarwal SK, Nephrology C-19 WG of IS of. Epidemiology, Genomic Structure, the Molecular Mechanism of Injury, Diagnosis and Clinical Manifestations of Coronavirus Infection: An Overview. *Indian J Nephrol* [Internet]. 2020/06/01. 2020;30(3):143–54. Available from: <https://pubmed.ncbi.nlm.nih.gov/33013059>
30. Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the angiotensin converting enzyme 2-angiotensin (1-7)-Mas receptor axis: Fetal programming, sex differences, and intracellular pathways. *Front Endocrinol (Lausanne)*. 2014;5(JAN):1–13.
31. Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. *J Mol Cell Cardiol* [Internet]. 2014;66:167–76. Available from: <http://dx.doi.org/10.1016/j.yjmcc.2013.11.017>
32. Li F, Li W, Farzan M, Harrison SC. Structural biology: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. *Science (80-)*. 2005;309(5742):1864–8.
33. Mythbusters [Internet]. [cited 2021 Jun 23]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters?gclid=CjwKCAjw8uGBhBAEiwAayu_9QptCA2ku5bjGexCjjDgvwW4wUdcC0_strS1IUYnZV4Y1vCPi2w-xRoCupIQAvD_BwE#vaccines
34. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *J Travel Med*. 2020;27(2):1–4.
35. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2. *Am J Respir Crit Care Med*. 2020;202(5):756–9.

36. Symptoms of COVID-19 | CDC [Internet]. [cited 2021 Jun 23]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>
37. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *J Infect*. 2020;81(2):e16–25.
38. Linder FE. National Health Survey. *Science* (80-). 1958;127(3309):1275–9.
39. Kemenkes RI. Hasil Riset Kesehatan Dasar Tahun 2018. Kementerian Kesehatan RI. 2018;53(9):1689–99.
40. WHO. Pernyataan WHO: Penggunaan tembakau dan COVID-19 [Internet]. [cited 2021 Jul 4]. Available from: <https://www.who.int/indonesia/news/detail/11-05-2020-pernyataan-who-penggunaan-tembakau-dan-covid-19>
41. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol* [Internet]. 2020;17(5):259–60. Available from: <http://dx.doi.org/10.1038/s41569-020-0360-5>
42. Alifano M, Alifano P, Forgez P, Iannelli A. Renin-angiotensin system at the heart of COVID-19 pandemic Marco. 2020;(January).
43. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J Am Med Assoc*. 2020;323(11):1061–9.
44. Rao S, Lau A, So HC. Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits. *Diabetes Care*. 2020;43(7):1416–26.
45. Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. *JCI Insight*. 2019;4(20).
46. Fernandez C, Rysä J, Almgren P, Nilsson J, Engström G, Orho-Melander M, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. *J Intern Med*. 2018;284(4):377–87.
47. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series. *N Engl J Med*. 2020;382(21):2012–22.
48. Yang J, Zheng Y, Gou X, Pu K, Chen Z. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis* [Internet]. 2020;94(March):91–5. Available

from: <https://pubmed.ncbi.nlm.nih.gov/32173574/>

49. Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-Alanoca A, Alarcon-De-la-Vega G, Alvarado-Arnez LE, Balderrama-Saavedra MA, et al. Risk factors for mortality in patients with Coronavirus Disease 2019 (COVID-19) in Bolivia: An analysis of the first 107 confirmed cases. *Le Infez Med.* 2020 Jun;28(2):238–42.
50. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. *Am J Hypertens.* 2020;33(5):373–4.
51. Zhang J jin, Dong X, Cao Y yuan, Yuan Y dong, Yang Y bin, Yan Y qin, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy Eur J Allergy Clin Immunol.* 2020;75(7):1730–41.
52. Chan JWM, Ng CK, Chan YH, Mok TYW, Lee S, Chu SYY, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). *Thorax.* 2003;58(8):686–9.
53. Badawi A, Gwan S. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. 2020;(January).
54. Qiu H, Tong Z, Ma P, Hu M, Peng Z, Wu W, et al. Intensive care during the coronavirus epidemic. *Intensive Care Med [Internet].* 2020;46(4):576–8. Available from: <https://doi.org/10.1007/s00134-020-05966-y>
55. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology.* 2018;23(2):130–7.
56. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol.* 2020;94(7):1–9.
57. Aditama P dr. TY, Sp.P(K), MARS, DTM&H, DTCE F. COVID-19 dalam tulisan Prof. Tjandra. 1384.
58. Setiyo Adi Nugroho INH. Efektivitas Dan Keamanan Vaksin Covid-19. *J Keperawatan.* 2021;9:47.
59. Marwan. Peran vaksin penanganan pandemi COVID19. *Fak Kedokt Univ Mulawarman - RSU A W Sjahranie Samarinda [Internet].* 2021;1(covid). Available from: <http://lp2m.unmul.ac.id/webadmin/public/upload/files/9584b64517cfe308eb6b115847cbe8e7.pdf>
60. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. 2020;(January).
61. Satria RMA, Tutupoho RV, Chalidyanto D. Analisis Faktor Risiko Kematian dengan Penyakit Komorbid Covid-19. *J Keperawatan Silampari.*

2020;4(1):48–55.

62. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson G, Moher D, et al. Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting - Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group B. *JAMA Neurol.* 2000;283:2008–12.
63. Listyoko AS, Djajalaksana S, Astuti T. Hubungan Merokok Dengan Derajat Keparahan Dan Mortalitas Pasien COVID-19 Rawat Inap di RS Saiful Anwar Malang. *Medica Hosp J Clin Med.* 2020;7(1A):137–43.
64. Ebuy H, Gessesse Z, Gebrecherkos T, Kebede Y, Weldegebreal A, Hagazi M, et al. International Journal of Infectious Diseases Clinical features and risk factors associated with morbidity and mortality among patients with COVID-19 in northern Ethiopia. *Int J Infect Dis [Internet].* 2021;105:776–83. Available from: <https://doi.org/10.1016/j.ijid.2021.03.037>
65. Castro MC, Gurzenda S, Macário EM, França GVA. Characteristics, outcomes and risk factors for mortality of 522 167 patients hospitalised with COVID-19 in Brazil: a retrospective cohort study. *BMJ Open.* 2021 May;11(5):e049089.
66. Shakira W, Hasani R, Ganapathy SS, Lin CZ, Rifin HM, Bahari MN, et al. Comorbidities and clinical features related to severe outcomes among COVID-19 cases in Selangor, Malaysia. 2021;12(1):46–52.
67. Ishtiaq R, Patti DK, Kumar A, Sandho G, Jacob K, Luthra K, et al. Clinical characteristics and outcomes of patients with Corona Virus Disease 2019 (COVID-19) at Mercy Health Hospitals , Toledo , Ohio. 2021;2019:1–11. Available from: <http://dx.doi.org/10.1371/journal.pone.0250400>
68. Rika J, Id M, Nyembu RK, Telo GM, Ngoy D, Sakobo TM, et al. PLOS ONE Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema , a public hospital in Kinshasa , in the Democratic Republic of Congo : A retrospective cohort study. 2020;1–15. Available from: <http://dx.doi.org/10.1371/journal.pone.0244272>
69. Puebla D, Watts A, Seashore J, Polychronopoulou E. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information . 2020;(January).
70. Id AP, Gillani FS, Shi Y, Hardesty A, Mccarthy M, Aridi J, et al. Predictors of severity and mortality among patients hospitalized with COVID-19 in Rhode Island. 2021;1–15. Available from: <http://dx.doi.org/10.1371/journal.pone.0252411>
71. Almazeedi S, Al-youha S, Jamal MH, Al-haddad M, Al-muhaini A, Al-ghimlas F, et al. EClinicalMedicine Characteristics , risk factors and outcomes among the fi rst consecutive 1096 patients diagnosed with

- COVID-19 in Kuwait. *EClinicalMedicine* [Internet]. 2020;24:100448. Available from: <https://doi.org/10.1016/j.eclinm.2020.100448>
72. Bergman J, Ballin M, Nordström A, Nordström P. Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. *Eur J Epidemiol*. 2021 Mar;36(3):287–98.
 73. Martins-Filho PR, Antunes de Souza Araújo A, Pereira LX, Quintans-Júnior LJ, de Souza Barboza W, Cavalcante TF, et al. Factors Associated with Mortality among Hospitalized Patients with COVID-19: A Retrospective Cohort Study. *Am J Trop Med Hyg*. 2021 Jan;104(1):103–5.
 74. Caliskan T, Saylan B. Smoking and comorbidities are associated with COVID-19 severity and mortality in 565 patients treated in Turkey: a retrospective observational study. *Rev Assoc Med Bras*. 2020 Dec;66(12):1679–84.
 75. Chang MC, Park Y-K, Kim B-O, Park D. Risk factors for disease progression in COVID-19 patients. *BMC Infect Dis*. 2020 Jun;20(1):445.
 76. Lee S-G, Park GU, Moon YR, Sung K. Clinical Characteristics and Risk Factors for Fatality and Severity in Patients with Coronavirus Disease in Korea: A Nationwide Population-Based Retrospective Study Using the Korean Health Insurance Review and Assessment Service (HIRA) Database. *Int J Environ Res Public Health*. 2020 Nov;17(22).
 77. Timberlake DT, Narayanan D, Ogbogu PU, Raveendran R. Severity of COVID-19 in hospitalized patients with and without atopic disease. *World Allergy Organ J* [Internet]. 2021;14(2):100508. Available from: <https://doi.org/10.1016/j.waojou.2021.100508>
 78. Liu K, Mubarik S, Shi F, Wen H, Zeng Z. Epidemiological characteristics of patients with severe COVID-19 infection in Wuhan, China: evidence from a retrospective observational study. 2020;1940–50.
 79. Wang S, Chen Z, Lin Y, Lin L, Lin Q, Fang S, et al. Clinical characteristics of 199 discharged patients with COVID-19 in Fujian Province : A multicenter retrospective study between. 2020;1–13. Available from: <http://dx.doi.org/10.1371/journal.pone.0242307>
 80. Jang JG, Hur J, Choi EY, Hong KS, Lee W, Ahn JH. Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu, Korea. *J Korean Med Sci*. 2020 Jun;35(23):e209.
 81. Jaspard M, Saliou M, Juchet S, Dienderé E, Serra B, Kojan R, et al. International Journal of Infectious Diseases Clinical presentation , outcomes and factors associated with mortality : A prospective study from three COVID-19 referral care centres in West Africa. 2021;108:45–52.
 82. Denova-Gutiérrez E, Lopez-Gatell H, Alomia-Zegarra JL, López-Ridaura R, Zaragoza-Jimenez CA, Dyer-Leal DD, et al. The Association of Obesity,

- Type 2 Diabetes, and Hypertension with Severe Coronavirus Disease 2019 on Admission Among Mexican Patients. *Obesity* [Internet]. 2020 Oct 1;28(10):1826–32. Available from: <https://doi.org/10.1002/oby.22946>
83. Parra-Bracamonte GM, Lopez-Villalobos N, Parra-Bracamonte FE. Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. *Ann Epidemiol.* 2020;52(January):93-98.e2.
 84. Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, et al. Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study. *J Korean Med Sci.* 2020 Jun;35(25):e237.
 85. Sedgwick P. Meta-analyses: how to read a funnel plot. 2:3–4.
 86. Guo FR. Smoking links to the severity of Covid-19: An update of a meta-analysis. *J Med Virol* [Internet]. :0–3. Available from: <http://dx.doi.org/10.1002/jmv.25967>
 87. Lippi G HB. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). 2020;(January).
 88. Vardavas CI, Nikitara K. COVID-19 and smoking : A systematic review of the evidence. 2020;(March):1–4.
 89. Prats-uribe A, Prieto-alhambra D, Petersen I. Smoking and COVID-19 Infection and Related Mortality : A Prospective Cohort Analysis of UK Biobank Data. 2021;(April).
 90. Salah HM, Sharma T, Mehta J. Smoking Doubles the Mortality Risk in COVID-19 : A Meta-Analysis of Recent Reports and Potential Mechanisms. 2020;12(10).
 91. Berlin I, Thomas D, Faou A Le, Cornuz J. COVID-19 and Smoking. 2020;1–3.
 92. Karanasos A, Aznaouridis K. Impact of Smoking Status on Disease Severity and Mortality of Hospitalized Patients With COVID-19 Infection : A Systematic Review and. 2020;(1):1657–9.
 93. Mondì A, Lorenzini P, Castillettì C, Gagliardini R, Lalle E, Corpolongo A, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information . 2020;(January).
 94. Petersen F, Yu X. Association of Cigarette Smoking , COPD , and Lung Cancer With Expression of SARS-CoV-2 Entry Genes in Human Airway Epithelial. 2020;7(March):1–10.
 95. Guoshuai Cai, Ph.D, Yohan Boss ´ e P. Tobacco Smoking Increases the Lung Gene. 2020;1557–9.

96. Huang I, Lim MA, Pranata R. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information . 2020;(January).
97. Pititto BDA, Dualib PM, Zajdenverg L, Dantas JR. Severity and mortality of COVID 19 in patients with diabetes , hypertension and cardiovascular disease : a meta - analysis. *Diabetol Metab Syndr* [Internet]. 2020;4:1–12. Available from: <https://doi.org/10.1186/s13098-020-00586-4>
98. Lestari N, Ichsan B, Kedokteran F, Surakarta UM, Lestari KN, Alamat MPH. Diabetes Melitus Sebagai Faktor Risiko Keparahan Dan Kematian Pasien Covid-19 : Meta-Analisis Diabetes Mellitus As a Risk Factor for Severity and Mortality of Covid-19 : a Meta-Analysis. *Biomedika*. 2020;13(1):83–94.
99. Bae JH. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat Rev Endocrinol* [Internet]. 2021;17(January). Available from: <http://dx.doi.org/10.1038/s41574-020-00435-4>
100. Luh Ade Dita Rahayu, 1 Jannatul Cahya Admiyanti, 1 Yumna Iftinan Khalda, 1 Fatikha Rudia Ahda, 1 Nur Feby Febiana Agistany, 1 Sastraningsih Setiawati, 1 Nabila Indah Shofiyanti 1 Cut Warnaini. Sebagai faktor komorbiditas utama terhadap mortalitas pasien covid-19 : sebuah studi literatur tujuan pustaka hypertension , diabetes mellitus , and obesity as the main comorbidity factors of mortality in covid-19 patients : a literature review. 2021;9.
101. Geng M-J, Wang L-P, Ren X, Yu J-X, Chang Z-R, Zheng C-J, et al. Risk factors for developing severe COVID-19 in China: an analysis of disease surveillance data. *Infect Dis poverty*. 2021 Apr;10(1):48.
102. Tiksnadi BB, Sylviana N, Cahyadi AI, Undarsa AC. Tinjauan Editorial Pustaka. 2020;41(2).
103. Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia : A systematic review , meta-analysis and meta-regression. 2020;(20).
104. Ahmad Alkautsar. HUBUNGAN PENYAKIT KOMORBID DENGAN TINGKAT KEPARAHAN PASIEN COVID-19. *J Med Utama*. 2021;03(01):1488–94.
105. Mishra P, Parveen R, Bajpai R, Samim M, Agarwal NB. Impact of cardiovascular diseases on severity of COVID-19 patients : A systematic review. 2021;50(1):52–60.
106. Sayer G, Griffin JM. COVID-19 and Cardiovascular Disease. 2020;2019:1648–55.

107. Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SHORT REPORT SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. 2009;39:618–25.
108. Rabbani G, Mohammad S, Islam S, Aziz M, Amin N, Marzan B, et al. Expert Review of Respiratory Medicine Pre-existing COPD is associated with an increased risk of mortality and severity in COVID-19 : a rapid systematic review and meta-analysis. *Expert Rev Respir Med* [Internet]. 2021;15(5):705–16. Available from: <https://doi.org/10.1080/17476348.2021.1866547>
109. Gerayeli F V, Milne S, Cheung C, Li X, Wei C, Yang T, et al. EClinicalMedicine COPD and the risk of poor outcomes in COVID-19 : A systematic review and meta-analysis. *EClinicalMedicine* [Internet]. 2021;33:100789. Available from: <https://doi.org/10.1016/j.eclinm.2021.100789>
110. Alqahtani FY, Aleanizy FS, El RA, Mohamed H, Alanazi MS, Mohamed N, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus : a retrospective study. 2019;
111. Team CDCC-19 R, Team CDCC-19 R, Team CDCC-19 R, Chow N, Fleming-Dutra K, Gierke R, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. *Morb Mortal Wkly Rep*. 2020;69(13):382–6.

